Search

Your search keyword '"Tortorella, C"' showing total 134 results

Search Constraints

Start Over You searched for: Author "Tortorella, C" Remove constraint Author: "Tortorella, C" Topic multiple sclerosis Remove constraint Topic: multiple sclerosis
134 results on '"Tortorella, C"'

Search Results

1. Neurophysiological methods for assessing and treating cognitive impairment in multiple sclerosis: A scoping review of the literature.

2. Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.

3. Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials.

4. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.

5. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.

6. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study

7. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.

8. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.

9. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.

10. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.

11. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.

12. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study.

13. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

14. Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.

15. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.

16. Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.

17. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.

18. Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.

19. Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.

20. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.

21. A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.

22. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.

23. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.

24. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.

25. Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group.

26. Informing MS patients on treatment options: a consensus on the process of consent taking.

27. Listening to the neurological teams for multiple sclerosis: the SMART project.

28. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study.

29. "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.

30. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.

31. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

32. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

33. Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease.

34. Prognostic indicators in pediatric clinically isolated syndrome.

35. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

36. Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances.

37. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.

38. A rare case of multiple sclerosis and McArdle disease.

39. Patient expression of emotions and neurologist responses in first multiple sclerosis consultations.

40. Natalizumab discontinuation and disease restart in pregnancy: a case series.

42. Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration.

43. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial.

44. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

45. Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments.

46. Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender.

47. Low serum urate levels are associated to female gender in multiple sclerosis patients.

48. Geographical variations in sex ratio trends over time in multiple sclerosis.

49. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?

50. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

Catalog

Books, media, physical & digital resources